Medexus Pharmaceuticals Inc. (TSE:MDP) Receives C$4.57 Consensus Price Target from Analysts

Shares of Medexus Pharmaceuticals Inc. (TSE:MDP) have earned a consensus rating of “Buy” from the seven brokerages that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and four have given a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is C$4.57.

Separately, Alliance Global Partners raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 11th.

Medexus Pharmaceuticals Price Performance

TSE:MDP opened at C$2.88 on Monday. The firm has a market cap of C$92.90 million, a price-to-earnings ratio of 144.00 and a beta of 1.60. The company has a 50 day moving average price of C$2.90 and a 200-day moving average price of C$2.85. Medexus Pharmaceuticals has a 1-year low of C$1.71 and a 1-year high of C$5.56.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.